Karen I Barnes

Summary

Affiliation: University of Cape Town
Country: South Africa

Publications

  1. pmc Pharmacokinetics and tolerability of artesunate and amodiaquine alone and in combination in healthy volunteers
    Catherine Orrell
    Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Anzio Road, Observatory, Cape Town, 7925, South Africa
    Eur J Clin Pharmacol 64:683-90. 2008
  2. pmc Effects of amodiaquine and artesunate on sulphadoxine-pyrimethamine pharmacokinetic parameters in children under five in Mali
    Mamadou M Tekete
    Molecular Epidemiology and Drug Resistance Unit, Malaria Research and Training Centre, Department of Epidemiology of Parasitic Diseases, Faculty of Medicine, Pharmacy and Dentistry, University of Bamako, P, O, Box 1805, Bamako, Mali
    Malar J 10:275. 2011
  3. pmc The rationale and plan for creating a World Antimalarial Resistance Network (WARN)
    Carol Hopkins Sibley
    Malar J 6:118. 2007
  4. doi request reprint Antimalarial dosing regimens and drug resistance
    Karen I Barnes
    Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa
    Trends Parasitol 24:127-34. 2008
  5. pmc World Antimalarial Resistance Network (WARN) IV: clinical pharmacology
    Karen I Barnes
    Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa
    Malar J 6:122. 2007
  6. pmc Impact of the large-scale deployment of artemether/lumefantrine on the malaria disease burden in Africa: case studies of South Africa, Zambia and Ethiopia
    Karen I Barnes
    Division of Clinical Pharmacology, Department of Medicine, University of Cape Town Faculty of Health Sciences, Anzio Road, Observatory, 7925, South Africa
    Malar J 8:S8. 2009
  7. pmc Interaction between artemether-lumefantrine and nevirapine-based antiretroviral therapy in HIV-1-infected patients
    T Kredo
    Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa
    Antimicrob Agents Chemother 55:5616-23. 2011
  8. pmc Association between the pharmacokinetics and in vivo therapeutic efficacy of sulfadoxine-pyrimethamine in Malawian children
    Fraction K Dzinjalamala
    University of Cape Town, Division of Clinical Pharmacology, K50 Old Main Building, Groote Schuur Hospital, Cape Town 7925, South Africa
    Antimicrob Agents Chemother 49:3601-6. 2005
  9. doi request reprint Increased gametocytemia after treatment: an early parasitological indicator of emerging sulfadoxine-pyrimethamine resistance in falciparum malaria
    Karen I Barnes
    Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa
    J Infect Dis 197:1605-13. 2008
  10. pmc Efficacy of sulphadoxine-pyrimethamine with or without artesunate for the treatment of uncomplicated Plasmodium falciparum malaria in southern Mozambique: a randomized controlled trial
    Elizabeth N Allen
    Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, South Africa
    Malar J 8:141. 2009

Collaborators

Detail Information

Publications35

  1. pmc Pharmacokinetics and tolerability of artesunate and amodiaquine alone and in combination in healthy volunteers
    Catherine Orrell
    Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Anzio Road, Observatory, Cape Town, 7925, South Africa
    Eur J Clin Pharmacol 64:683-90. 2008
    ..As no pharmacokinetic data on this combination have been published to date, we investigated its pharmacokinetic interactions and tolerability in healthy volunteers in Africa...
  2. pmc Effects of amodiaquine and artesunate on sulphadoxine-pyrimethamine pharmacokinetic parameters in children under five in Mali
    Mamadou M Tekete
    Molecular Epidemiology and Drug Resistance Unit, Malaria Research and Training Centre, Department of Epidemiology of Parasitic Diseases, Faculty of Medicine, Pharmacy and Dentistry, University of Bamako, P, O, Box 1805, Bamako, Mali
    Malar J 10:275. 2011
    ..Yet, limited data is available on pharmacokinetic interactions between these drugs...
  3. pmc The rationale and plan for creating a World Antimalarial Resistance Network (WARN)
    Carol Hopkins Sibley
    Malar J 6:118. 2007
    ..WARN will serve as a public resource to guide antimalarial drug treatment and prevention policies and to help confirm and characterize the new emergence of new resistance to antimalarial drugs and to contain its spread...
  4. doi request reprint Antimalarial dosing regimens and drug resistance
    Karen I Barnes
    Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa
    Trends Parasitol 24:127-34. 2008
    ..There is an urgent need for studies to optimise antimalarial dosage regimens in infants, young children and pregnant women, both to improve cure rates and to prolong the useful therapeutic lives of antimalarial drugs...
  5. pmc World Antimalarial Resistance Network (WARN) IV: clinical pharmacology
    Karen I Barnes
    Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa
    Malar J 6:122. 2007
    ....
  6. pmc Impact of the large-scale deployment of artemether/lumefantrine on the malaria disease burden in Africa: case studies of South Africa, Zambia and Ethiopia
    Karen I Barnes
    Division of Clinical Pharmacology, Department of Medicine, University of Cape Town Faculty of Health Sciences, Anzio Road, Observatory, 7925, South Africa
    Malar J 8:S8. 2009
    ..Artemisinin-based combination therapy has made a substantial contribution to reducing the burden of malaria in sub-Saharan Africa...
  7. pmc Interaction between artemether-lumefantrine and nevirapine-based antiretroviral therapy in HIV-1-infected patients
    T Kredo
    Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa
    Antimicrob Agents Chemother 55:5616-23. 2011
    ..The mechanism of the lumefantrine interaction remains to be elucidated. Studies investigating the interaction of nevirapine and artemether-lumefantrine in HIV-infected patients with malaria are urgently needed...
  8. pmc Association between the pharmacokinetics and in vivo therapeutic efficacy of sulfadoxine-pyrimethamine in Malawian children
    Fraction K Dzinjalamala
    University of Cape Town, Division of Clinical Pharmacology, K50 Old Main Building, Groote Schuur Hospital, Cape Town 7925, South Africa
    Antimicrob Agents Chemother 49:3601-6. 2005
    ..falciparum should be interpreted with caution and needs further validation...
  9. doi request reprint Increased gametocytemia after treatment: an early parasitological indicator of emerging sulfadoxine-pyrimethamine resistance in falciparum malaria
    Karen I Barnes
    Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa
    J Infect Dis 197:1605-13. 2008
    ..Although malaria treatment aims primarily to eliminate the asexual blood stages that cause illness, reducing the carriage of gametocytes is critical for limiting malaria transmission and the spread of resistance...
  10. pmc Efficacy of sulphadoxine-pyrimethamine with or without artesunate for the treatment of uncomplicated Plasmodium falciparum malaria in southern Mozambique: a randomized controlled trial
    Elizabeth N Allen
    Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, South Africa
    Malar J 8:141. 2009
    ..An artemisinin-based combination therapy, artesunate (AS) plus sulphadoxine-pyrimethamine (SP), was compared to SP monotherapy to provide evidence of further treatment options in southern Mozambique...
  11. ncbi request reprint Malaria pharmacovigilance in Africa: lessons from a pilot project in Mpumalanga Province, South Africa
    Ushma Mehta
    Division of Clinical Pharmacology, University of Cape Town, Cape Town, South Africa
    Drug Saf 30:899-910. 2007
    ....
  12. pmc How experiences become data: the process of eliciting adverse event, medical history and concomitant medication reports in antimalarial and antiretroviral interaction trials
    Elizabeth N Allen
    Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa
    BMC Med Res Methodol 13:140. 2013
    ..This study compared methods for eliciting such data and explored reasons for dissimilar participant responses...
  13. ncbi request reprint Sulfadoxine-pyrimethamine pharmacokinetics in malaria: pediatric dosing implications
    Karen I Barnes
    Division of Clinical Pharmacology and Department of Statistical Sciences, University of Cape Town, Cape Town, South Africa
    Clin Pharmacol Ther 80:582-96. 2006
    ..Despite decades of widespread use, there are few data to inform dose recommendations...
  14. pmc Nonlinear mixed effects modeling of gametocyte carriage in patients with uncomplicated malaria
    Greg B Distiller
    Department of Statistical Sciences, University of Cape Town, Cape Town, South Africa
    Malar J 9:60. 2010
    ..The objective of this research was to directly model observed gametocyte densities over time, during the primary infection...
  15. pmc Should countries implementing an artemisinin-based combination malaria treatment policy also introduce rapid diagnostic tests?
    Charlotte M Zikusooka
    Health Economics Unit, Department of Public Health and Family Medicine, University of Cape Town, Anzio Road, Observatory, 7925 Cape Town, South Africa
    Malar J 7:176. 2008
    ..This motivates for this assessment of the cost-effectiveness of routine use of rapid diagnostic tests (RDTs) as an integral part of deploying artemisinin-based combination therapies (ACTs)...
  16. pmc Effect of artemether-lumefantrine policy and improved vector control on malaria burden in KwaZulu-Natal, South Africa
    Karen I Barnes
    Division of Clinical Pharmacology, University of Cape Town, Cape Town, South Africa
    PLoS Med 2:e330. 2005
    ..Malaria is diagnosed definitively and treatment is provided free of charge in reasonably accessible public-sector health-care facilities...
  17. ncbi request reprint Population biology and antimalarial resistance: The transmission of antimalarial drug resistance in Plasmodium falciparum
    Karen I Barnes
    Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town 7925, South Africa
    Acta Trop 94:230-40. 2005
    ..Artemisinin-based combination therapies are the only antimalarials currently available which rapidly reduce both asexual and gametocyte stages of the P. falciparum lifecycle...
  18. ncbi request reprint Blood folate concentrations and in vivo sulfadoxine-pyrimethamine failure in Malawian children with uncomplicated Plasmodium falciparum malaria
    Fraction K Dzinjalamala
    Division of Pharmacology, University of Cape Town, Cape Town, South Africa
    Am J Trop Med Hyg 72:267-72. 2005
    ....
  19. ncbi request reprint Artemisinin-based combination therapy reduces expenditure on malaria treatment in KwaZulu Natal, South Africa
    Charlotte Muheki
    Health Sciences Faculty, University of Cape Town, South Africa
    Trop Med Int Health 9:959-66. 2004
    ..This paper explores some economic aspects of the implementation of artemether-lumefantrine (AL) to replace sulphadoxine-pyrimethamine (SP) in the KwaZulu Natal (KZN) province, South Africa...
  20. pmc Adverse drug reactions in adult medical inpatients in a South African hospital serving a community with a high HIV/AIDS prevalence: prospective observational study
    Ushma Mehta
    Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Observatory 7925, South Africa
    Br J Clin Pharmacol 65:396-406. 2008
    ..ADRs in HIV-infected patients were less likely to be preventable...
  21. pmc Exploring the seasonality of reported treated malaria cases in Mpumalanga, South Africa
    Sheetal Prakash Silal
    Department of Statistical Sciences, University of Cape Town, Cape Town, South Africa
    PLoS ONE 8:e76640. 2013
    ..These findings may be useful as they enhance the understanding of the current incidence pattern and may inform mathematical models that enable one to predict the impact changes in these drivers will have on malaria transmission. ..
  22. pmc Evaluating harm associated with anti-malarial drugs: a survey of methods used by clinical researchers to elicit, assess and record participant-reported adverse events and related data
    Elizabeth N Allen
    Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa
    Malar J 12:325. 2013
    ..To explore how these data are obtained in malaria drug studies, a descriptive online survey of clinical researchers was conducted during 2012 and 2013...
  23. pmc Integration of data from multiple sources for simultaneous modelling analysis: experience from nevirapine population pharmacokinetics
    Elin Svensson
    Department of Pharmaceutical Bioscience, Uppsala University, Sweden
    Br J Clin Pharmacol 74:465-76. 2012
    ..To propose a modelling strategy to efficiently integrate data from different sources in one simultaneous analysis, using nevirapine population pharmacokinetic data as an example...
  24. ncbi request reprint Comment on: Audiometric changes associated with the treatment of uncomplicated falciparum malaria with co-artemether
    Ushma Mehta
    Trans R Soc Trop Med Hyg 99:313-4; author reply 314-5. 2005
  25. pmc Seven years of regional malaria control collaboration--Mozambique, South Africa, and Swaziland
    Brian L Sharp
    Malaria Research Programme, Medical Research Council, Durban, South Africa
    Am J Trop Med Hyg 76:42-7. 2007
    ..The success of the program in reducing malaria transmission throughout the target area provides a strong argument for investment in regional malaria control...
  26. ncbi request reprint Measuring resistance to malaria
    Karen I Barnes
    S Afr Med J 94:36-7. 2004
  27. pmc World Antimalarial Resistance Network I: clinical efficacy of antimalarial drugs
    Ric N Price
    International Health Program, Menzies School of Health Research and Charles Darwin University, Darwin, Northern Territory, Australia
    Malar J 6:119. 2007
    ..This resource will help guide rational drug policies that optimize antimalarial drug use, in the hope that the emergence and spread of resistance to new drugs can be, if not prevented, at least delayed...
  28. ncbi request reprint Rolling back malaria in Africa
    Karen I Barnes
    S Afr Med J 97:36-7. 2007
  29. pmc Population pharmacokinetics of artesunate and dihydroartemisinin following intra-rectal dosing of artesunate in malaria patients
    Julie A Simpson
    Centre for Molecular, Environmental, Genetic and Analytic Epidemiology, The University of Melbourne, Melbourne, Australia
    PLoS Med 3:e444. 2006
    ..We studied the population pharmacokinetics of intra-rectal artesunate and the relationship with parasitological responses in patients with moderately severe falciparum malaria...
  30. pmc Antimalarial treatment with artemisinin combination therapy in Africa
    Grace Malenga
    BMJ 331:706-7. 2005
  31. pmc Differential effect of regional drug pressure on dihydrofolate reductase and dihydropteroate synthetase mutations in southern Mozambique
    Jaishree Raman
    Malaria Lead Programme, Medical Research Council, Durban, KwaZulu Natal, South Africa
    Am J Trop Med Hyg 78:256-61. 2008
    ..Our results show that drug pressure can exert its influence at a regional level rather than merely at a national level...
  32. ncbi request reprint A network to monitor antimalarial drug resistance: a plan for moving forward
    Carol Hopkins Sibley
    Department of Genome Sciences, University of Washington, Seattle, WA, USA
    Trends Parasitol 24:43-8. 2008
    ....
  33. ncbi request reprint The pharmacokinetics of intravenous artesunate in adults with severe falciparum malaria
    Paul N Newton
    Faculty of Tropical Medicine, Mahidol University, 420 6 Rajvithi Rd, Bangkok 10400, Thailand
    Eur J Clin Pharmacol 62:1003-9. 2006
    ..The choice of doses used has been empirical. To inform dosage recommendations we assessed the pharmacokinetics of intravenous artesunate after the first dose...
  34. ncbi request reprint WHO, the Global Fund, and medical malpractice in malaria treatment
    Amir Attaran
    Royal Institute of International Affairs, London, UK
    Lancet 363:237-40. 2004
  35. ncbi request reprint The World Bank: false financial and statistical accounts and medical malpractice in malaria treatment
    Amir Attaran
    Institute of Population Health and Faculty of Law, University of Ottawa, Ottawa, Ontario, K1N 6N5, Canada
    Lancet 368:247-52. 2006